 |
|
Realizing the Benefits of Practical Clinical Trials—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: We are heartened by the comments of Drs Ofman and Lubeck, who acknowledge the important role for the pharmaceutical industry in supporting PCTs that reliably compare risks, benefits, and costs of competing technologies. We agree that the production of high-quality evidence will not by itself influence the decisions of consumers, clinicians, and policy makers. Clearly there is also a need for organizational strategies and systems that will increase the use of clinical interventions proven to be effective. Many public and private health care organizations are devoting considerable attention and resources to the measurement and improvement of health care quality.1-2
While more progress on implementation is critical, the supply of relevant, accurate information remains an important limitation in providing high-quality health care. We agree that a primary stimulus to the production of high-quality data will be the consistent and transparent use of this information by health care decision makers. . . . [Full Text of this Article]
Sean R. Tunis, MD, Msc
Centers for Medicare & Medicaid Services
Baltimore, Md
Daniel B. Stryer, MD
Agency for Healthcare Research and Quality
Rockville, Md
RELATED ARTICLES
Realizing the Benefits of Practical Clinical Trials
Joshua J. Ofman and Deborah P. Lubeck
JAMA. 2004;291(4):425-426.
EXTRACT
| FULL TEXT
Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy
Sean R. Tunis, Daniel B. Stryer, and Carolyn M. Clancy
JAMA. 2003;290(12):1624-1632.
ABSTRACT
| FULL TEXT
|
